StudyFinder
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
Recruiting
To determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), doxorubicin, and cyclophosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive probability of success in a subsequent phase 3 trial for each possible biomarker signature.
18 years and over
Inclusion Criteria:
• invasive breast cancer confirmed by biopsy
• tumor is at least 2.5 cm in size
• no prior chemotherapy for this cancer
• no restrictions in activity or partially restricted with work, but able to independently care for self
• willing to have another breast biopsy
• not pregnant or breast feeding
• consult study staff for additional requirements
Exclusion Criteria:
• other medical or mental health diagnosis that would limit compliance with study requirements
Cancer
Breast Cancer, Breast Tumors, I-SPY, ISPY, ISPY2
Douglas Yee - yeexx006@umn.edu
Douglas Yee, MD
STUDY00011111
38844
See this study on ClinicalTrials.gov